Glaxo Claims OTC Switch Dominance With An Eye Toward Xenical In 2006
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline believes an OTC switch of the prescription weight-loss drug Xenical (orlistat) could have the same success as its nonprescription nicotine replacement therapy offerings
You may also be interested in...
GSK's Quesnelle Brings Expertise In Switch To Consulting Arena
Through 30 years working in the pharmaceutical industry, George Quesnelle became a leading expert on the Rx-to-OTC switch process. At GlaxoSmithKline, he led the charge in switching Nicorette and NicoDerm CQ smoking cessation products, as well as alli for weight loss.
GSK's Quesnelle Brings Expertise In Switch To Consulting Arena
Through 30 years working in the pharmaceutical industry, George Quesnelle became a leading expert on the Rx-to-OTC switch process. At GlaxoSmithKline, he led the charge in switching Nicorette and NicoDerm CQ smoking cessation products, as well as alli for weight loss.
GSK's Quesnelle Brings Expertise In Switch To Consulting Arena
Through 30 years working in the pharmaceutical industry, George Quesnelle became a leading expert on the Rx-to-OTC switch process. At GlaxoSmithKline, he led the charge in switching Nicorette and NicoDerm CQ smoking cessation products, as well as alli for weight loss.